Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gypsophila: Tocilizumab in Pediatric COVID-19
NCT05164133Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 11
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Roche. Primary endpoints: Serum concentration of Tocilizumab, Maximum Serum Concentration and 4 more. Started Jun 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05164133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164133.